Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 2Vaccinia 1Solid Tumors 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasm Metastasis 1Gastric Adenocarcinoma 1Fallopian Tube Neoplasms 1Breast Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

pembrolizumab 6Cetuximab 5olaparib 3atezolizumab 3Injections 3fludarabine 2Trastuzumab 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2zimberelimab 1zansecimab 1tocilizumab 1taxane 1spartalizumab 1somatostatin receptor 2 1ribociclib 1pralsetinib 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1lenvatinib 1ipatasertib 1inavolisib 1fludarabine phosphate 1entrectinib 1encorafenib 1durvalumab 1dapagliflozin 1cemiplimab 1brigimadlin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × taxane × 1 year × Clear all
NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

ABL Bio, Inc.

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡